How does capillary electrophoresis (CE) as an orthogonal peptide purity method differ from HPLC area percent?
Reversed-phase HPLC remains the usual purity assay for synthetic research peptides because it is widely transferred and sensitive to many deletion, insertion and oxidation products. Its selectivity is hydrophobic. Two species with similar side-chain polarity can share a retention time even when net charge differs. Deamidation, isoaspartate formation, a protecting-group remnant that changes ionisation, and some truncations are related substances for which charge, not only hydrophobicity, is the discriminating property. Capillary zone electrophoresis separates the same sample by electrophoretic mobility in an open tube. A laboratory treats CE as orthogonal when the critical impurity is expected to change charge-to-size ratio more than retention on a C18 or C8 phase. Orthogonality is a documented demonstration, not a slogan. The second method must resolve a critical pair that the first method does not, or confirm that a specified impurity is below a stated reporting threshold. An electropherogram without method identity, capillary description, buffer, voltage, detection wavelength, migration-time window and integration rules is an untraceable trace. Buyers comparing Australian research lots should ask whether the reported figure is chromatographic area percent, electrophoretic area percent, or both, and whether the two were reconciled rather than averaged. Published CE purity work on other charged analytes shows why the attribute must be named. Malsch and colleagues assessed purity of glycosaminoglycan-related compounds by capillary electrophoresis, a case in which charge density dominates separation (DOI:10.1002/elps.1150170219). Morin reviewed chromatographic and electrophoretic techniques for chiral pharmaceutical separation and presented electrophoresis as a distinct selectivity tool (PMID:19596097). Neither paper is a synthetic-peptide monograph. They support a narrower, accurate reading: electrophoretic purity is a separate result. A mobility match to a reference standard supports identity but does not prove sequence; that remains a mass-spectrometric question.
How do mobility, electroosmotic flow and capillary coating control peptide zones?
In free-solution CE the observed mobility is electrophoretic mobility plus electroosmotic flow. EOF moves bulk buffer toward the cathode in an uncoated fused-silica capillary whose wall silanols are ionised. At acidic pH, common for basic peptides, EOF slows, cationic peptides adsorb to the wall, peaks tail, and migration-time precision worsens unless the surface is managed. A polyacrylamide or other neutral coating suppresses EOF and limits adsorption. Assi and colleagues determined propranolol enantiomeric purity by CE with dual cyclodextrins and a polyacrylamide-coated capillary, showing that coating and selector chemistry define the method (DOI:10.1002/(sici)1522-2683(19990901)20:13<2723::aid-elps2723>3.3.co;2-f). That analyte was not a peptide. The documentation lesson transfers: a peptide method that depends on a coated capillary must name the coating, because an uncoated repeat will not reproduce migration order. Buffer pH is set against the peptide isoelectric point and the pKa values of acidic and basic residues. A shift of a few tenths of a pH unit can reverse the mobility difference between a deamidated impurity and the parent. Ionic strength changes current and resolution; excess current heats the capillary, broadens zones and alters viscosity. Cyclodextrins and organic modifiers change selectivity and also viscosity and EOF, so they are critical parameters, not cosmetic additives. Underivatised peptides are usually detected by ultraviolet absorbance near 200 to 214 nm, where many buffer components also absorb. Diluent blanks, and blanks of stressed buffer, are therefore specificity evidence. Sample solvent creates false peaks and distorted zones. Low-conductivity diluent can stack a peptide into a sharp zone; high salt can defocus it. Acetic acid diluents used for some basic research peptides must be shown not to place a system peak inside the main-component window. Migration time should be expressed relative to an internal standard or a reference standard in the same sequence, not as a clock time copied from an older capillary.
When should CE-SDS be read as size-based purity beside charge-based CE?
CE-SDS separates SDS-complexed species in a sieving polymer. SDS gives a broadly similar charge density, so migration reflects hydrodynamic size more than native charge. The orthogonal map is then three-way: reversed-phase HPLC reports hydrophobicity, free-solution CE reports charge-to-size, and CE-SDS reports size under denaturing conditions. For short synthetic peptides the sieving effect is often weak, and free-solution CE or HPLC may be more informative. CE-SDS is worth specifying when the material is long, disulfide-linked, conjugated, or suspected of fragments and aggregates that one reversed-phase peak does not describe. Thorat and colleagues developed and validated CE-SDS for purity of pertussis toxin, filamentous haemagglutinin and pertactin (DOI:10.1016/j.vaccine.2023.08.010). Li and colleagues reported interlaboratory validation of CE-SDS for monoclonal antibodies (DOI:10.1002/elps.202000396). These are protein methods, not short-peptide monographs. The quality-system pattern is what transfers: defined sample preparation, reducing and non-reducing conditions, agreed acceptance criteria, and a comparison across laboratories before the result is used for disposition. A peptide file borrowing that pattern should state reduced or non-reduced status, the polymer and capillary kit, and how fragments were distinguished from system peaks. Raffaele and colleagues developed microchip CE for purity and integrity of mRNA in lipid nanoparticle vaccines (DOI:10.1002/elps.202100272). The analyte is not a peptide. The attribute split still belongs on a peptide certificate: purity (unrelated components absent) and integrity (intended chain intact) are not one number. A microchip trace may suit screening because the path is short, but it is not a lot-release assay until specificity, precision and a reporting threshold are established on that platform. If CE-SDS and HPLC disagree, the correct next step is identification by mass spectrometry or a qualified marker, not an average of the two area-percent figures.
How is a capillary electrophoresis purity method developed and validated?
Sokoließ and colleagues described method development and validation in CE for enantiomeric purity testing of basic pharmaceutical ingredients (DOI:10.1002/elps.200410257). Muijselaar and colleagues validated a CE enantiomeric-purity method for the basic compound SLV307 (DOI:10.1002/elps.200406022). The attribute was enantiomeric purity, not peptide deletions. The reusable part is the validation skeleton, not the selector recipe. Development starts from an analytical target profile: impurities to be separated, reporting threshold, salt form and detection. Critical pairs for a synthetic peptide are often parent versus deamidated species, parent versus a deletion sequence, and, where racemisation is plausible, parent versus a diastereomer. Resolution targets are set before optimisation. Selector type and concentration, buffer pH and concentration, coating, voltage, temperature and sample-introduction mode are then varied in a planned design. One-factor changes can hide interactions, such as pH with cyclodextrin concentration, that reverse migration order. Once the method is fixed, validation covers specificity against diluent, blank and available related substances; linearity of the main component and of a marker impurity; precision of migration time and area percent; accuracy by standard addition where a qualified impurity exists; range; and a reporting threshold linked to signal-to-noise or a low-level standard. Robustness includes small changes in pH, buffer concentration, voltage and temperature, plus capillary-to-capillary repeatability. Each sequence needs system suitability: critical-pair resolution or a surrogate, a current window, and a blank free of peaks in the main-component window. Failed suitability invalidates the sequence. CE area percent is not interchangeable with HPLC area percent. Response factors, stacking and detector path length differ. The report must label the result as CE area percent by the named method. If an impurity response factor is unknown, say so. Corrected peak area, area divided by migration time, compensates for slower zones dwelling in the detector. If corrected areas are used, the calculation must be stated so the peak table can be reconciled with the purity sentence.
How does quality by design structure chiral purity work in capillary electrophoresis?
Racemisation during coupling can introduce diastereomers that a standard achiral C18 method resolves poorly. Chiral CE, with a cyclodextrin or other selector in the background electrolyte, measures enantiomeric or diastereomeric purity. It is not a general assay for deletions and truncations, and a certificate should not label it as one. Krait and colleagues reported quality-by-design development of CE methods for chiral purity of dexmedetomidine and for enantiomeric purity of tenofovir (DOI:10.1002/elps.201800100; DOI:10.1002/elps.202100345). In that setting, quality by design means an analytical target profile, critical method parameters, a design space in which resolution and precision stay acceptable, and a control strategy rather than a single untested point. A peptide stereochemical profile might set minimum resolution between parent and a named diastereomer, a limit on relative migration-time drift, and a reporting threshold for the undesired stereoisomer. Selector concentration, pH and temperature can define the design space. Routine work stays inside it; a move outside it is a documented method change. Morin mapped why both chromatography and electrophoresis remain in use for chiral separations: electrophoresis changes the selector environment, often at low selector consumption, while chromatography may isolate a marker more readily (PMID:19596097). The lot record should name the selector, state whether the method is enantioselective or only diastereoselective, and quote critical-pair resolution from system suitability. One peak does not prove optical purity if the method was never shown to resolve the undesired stereoisomer. Specificity needs a racemised marker, a qualified diastereomer, or a forced-racemisation sample. Australian procurement should request stereochemical CE only when sequence and route make racemisation a credible risk. It does not replace HPLC related-substances testing, amino-acid analysis or tandem mass spectrometry, and it supports no claim about biological activity.
What should an Australian peptide certificate record for an orthogonal CE result?
A CE entry on a research peptide certificate is a data package, not a percentage parked beside the HPLC result. The identification block names analyte, lot, concentration basis, diluent, method identifier, analysis date, instrument, capillary internal diameter, length and coating, buffer and pH, voltage, temperature, wavelength, sample-introduction mode, and whether corrected areas were used. Without that block a later laboratory cannot tell whether a repeat is a true comparison. The result block lists relative migration time, area percent, peak type and every peak above the reporting threshold. Unknowns stay labelled unknown. System suitability sits beside the sample: critical-pair resolution, migration-time precision if replicates were made, blank conclusion and current stability. If suitability failed and the sequence was repeated, the failure remains in the raw-data index even when only the valid result is copied to the customer certificate. Reconciliation is a sentence, not an average. A sound form states the HPLC area percent and method, the CE area percent and method, whether the deamidated marker was resolved and below the reporting threshold, and which unknowns remain unidentified pending mass spectrometry. Averaging the two percentages hides selectivity. If CE was not run, the certificate must not imply that it was. A stated scope limit is more useful to an Australian reviewer than a decorative trace. File name, sample-set identifier and reviewer sign-off must match the lot on the vial and on the HPLC report. Original integration and an audit trail for any reintegration are part of the same data-integrity expectation as for liquid chromatography. ClaraScience treats these records as research documentation of identity, purity and lot traceability. They are not evidence of a biological effect.
Frequently asked questions
Is capillary electrophoresis a substitute for HPLC when reporting peptide purity?
Capillary electrophoresis is orthogonal to reversed-phase HPLC, not a substitute for it. HPLC area percent and CE area percent respond to different selectivity, so one cannot replace the other on a certificate. Use CE to test whether a charge- or size-based impurity was hidden under the HPLC main peak, and keep HPLC for the hydrophobic related-substances profile. Report each figure under its method name. Do not average them, and do not read either figure as evidence of a biological effect.
Does a single CE peak confirm peptide identity and sequence?
No. A migration-time match to a qualified reference standard supports identity within the method's selectivity. It does not prove amino-acid sequence, terminal modifications or disulfide connectivity. Those attributes require mass spectrometry, and often tandem mass spectrometry or amino-acid analysis, cross-checked to the same lot number. CE is a purity and orthogonal-separation tool. If the method has not been shown to resolve a named impurity, a single peak only shows that nothing detectable by that method was separated from the main zone.
When is CE-SDS more informative than free-solution CE for a peptide lot?
Free-solution CE separates by charge-to-size ratio and is usually the more informative electrophoretic check for short synthetic peptides, including many deamidated species. CE-SDS separates SDS-complexed molecules by size in a sieving polymer. It is more relevant for longer chains, disulfide-linked materials, conjugates, fragments and aggregates, and only when the peptide actually sieves. State whether the run was reducing or non-reducing. Protein CE-SDS validations, including interlaboratory monoclonal-antibody work, illustrate transfer and acceptance-criteria practice; they are not automatic specifications for a short research peptide.
Why can a chiral CE method not be filed as overall peptide purity?
Chiral CE answers a stereochemical question: whether a selector resolves the parent from an undesired enantiomer or diastereomer. It does not profile deletions, truncations, oxidation or most protecting-group remnants. A smooth main peak proves optical purity only if specificity was shown with a racemised marker, a qualified diastereomer or a forced-racemisation sample. The certificate should name the selector and quote critical-pair resolution from system suitability. Stereochemical purity is an additional attribute, requested when the route makes racemisation credible, not a replacement related-substances assay.
Which CE metadata should an Australian lot file include?
Record analyte, lot, diluent, method identifier, date, instrument, capillary dimensions and coating, buffer identity and pH, voltage, temperature, wavelength, sample-introduction mode, and whether areas were corrected for migration time. Add system suitability, the blank conclusion, the reporting threshold and reviewer sign-off matched to the vial lot and the HPLC report. Name every peak above the threshold. If CE was not performed, do not imply an orthogonal electrophoretic result. These fields support traceability for research procurement. They are not use instructions.
How should HPLC and CE purity figures be reconciled?
Place the two results in one traceable sentence that keeps method identity. State the HPLC area percent and method, the CE area percent and method, which specified impurities were resolved in each, and which peaks remain unidentified. Send unidentified peaks to mass spectrometry or a qualified marker rather than renaming them to force agreement. Do not average the percentages. Corrected CE areas must be declared if used. Disagreement is a selectivity finding, not a reason to discard the less convenient trace.
References
- PMID:19596097 — [Separation of chiral pharmaceutical drugs by chromatographic and electrophoretic techniques] — Ann Pharm Fr — 2009
- DOI:10.1002/elps.200410257 — Approach to method development and validation in capillary electrophoresis for enantiomeric purity testing of active basic pharmaceutical ingredients — ELECTROPHORESIS — 2005
- DOI:10.1002/elps.201800100 — Quality by design‐assisted development of a capillary electrophoresis method for the chiral purity determination of dexmedetomidine — ELECTROPHORESIS — 2018
- DOI:10.1002/elps.202100345 — Quality by design‐assisted development of a capillary electrophoresis method for the enantiomeric purity determination of tenofovir — ELECTROPHORESIS — 2022
- DOI:10.1016/j.vaccine.2023.08.010 — Development and validation of capillary electrophoresis sodium dodecyl sulfate (CE-SDS) method for purity analysis of pertussis toxin, filamentous haemagglutinin and pertactin antigens — Vaccine — 2023
- DOI:10.1002/elps.1150170219 — Purity of glycosaminoglycan‐related compounds using capillary electrophoresis — ELECTROPHORESIS — 1996
- DOI:10.1002/elps.202100272 — Development of a microchip capillary electrophoresis method for determination of the purity and integrity of mRNA in lipid nanoparticle vaccines — ELECTROPHORESIS — 2022
- DOI:10.1002/elps.200406022 — Development and validation of a capillary electrophoresis method for the enantiomeric purity determination of SLV307, a basic potential antipsychotic compound — ELECTROPHORESIS — 2004
- DOI:10.1002/(sici)1522-2683(19990901)20:13<2723::aid-elps2723>3.3.co;2-f — Enantiomeric purity determination of propranolol by capillary electrophoresis using dual cyclodextrins and a polyacrylamide-coated capillary — Electrophoresis — 1999
- DOI:10.1002/elps.202000396 — Interlaboratory method validation of capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) methodology for analysis of mAbs — ELECTROPHORESIS — 2021
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
